A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)

Study Summary

The main goal of this study is to characterize presentation, clinical course, and long-term outcomes of myocarditis temporally associated with administration of mRNA-1273 (SPIKEVAX) COVID-19 vaccine.

Conditions

Myocarditis

Interventions / Drugs

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment1500 participants

Primary Completion—

Lead SponsorModernaTX, Inc.

Data Retrieved2026-04-11 02:55:38.209329+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.